HealthdirectFree Australian health advice you can count on.

( ARTG ) Non-small cell lung cancer (NSCLC), IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours equal to or greater than 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements., IMFINZI is indicated for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy (CRT).,Small cell lung cancer (SCLC), IMFINZI as monotherapy is indicated for the treatment of adult patients with limited-stage sma‍‍‍‍‍‍​​​‍​​​​​​ll cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT)., IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).,Biliary tract cancer (BTC),IMFINZI in combination with gemcitabine and cisplatin is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).,Hepatocellular carcinoma (HCC),IMFINZI in combination with tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD- 1/PD-L1 inhibitor.,Endometrial cancer,IMFINZI in combination with carboplatin and paclitaxel, followed by IMFINZI monotherapy, is indicated for the first-line treatment of patients with primary advanced or recurrent endometrial cancer.,Bladder cancer,IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of adults with muscle invasive bladder cancer (MIBC).,Gastric and gastroesophageal junction (GOJ) cancer (GC/GOJC),IMFINZI in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant IMFINZI monotherapy, is indicated for the treatment of adults with resectable gastric or gastroesophageal junction adenocarcinoma.